RxDoctor Payments Data

Kari Edling

Endocrinology, Diabetes & Metabolism · Phoenix, AZNPI 1295987089

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.4%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Lilly USA, LLC at 48.7% of the total. Reporting peaked in 2019 at $16,539 and has fallen 99.7% since, to $50 in 2023.

$22,972in general payments, 2019–2025

Across 200 payments — averaging $114.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$11K
  • Boehringer Ingelheim$8K
  • Novo Nordisk$2K
  • Amgen$266
  • AstraZeneca$218
  • Corcept Therapeutics$217
  • plus $1K from 22 others

What the payments were for

  • Consulting fees$4,41019%
  • Speaking & faculty fees$13,41358%
  • Travel & lodging$1,7928%
  • Food & beverage$3,34915%
  • Education$80%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,972 in reported general payments places this provider in the 85th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Other endocrinology, diabetes & metabolism in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →